Parnax Lab Ltd.

86.94 -0.42 ▼-0.5%

23 February 2024, 04:01:00 PM
Volume: 9,093

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.naxparlab.com
Market Cap 99.86 Cr.
Enterprise Value(EV) 147.48 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 7.67 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 11.34 Trailing Twelve Months Ending 2023-12
Industry PE 41.88 Trailing Twelve Months Ending 2023-12
Book Value / Share 60.53 Trailing Twelve Months Ending 2023-12
Price to Book Value 1.44 Calculated using Price: 86.94
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 1.15 Cr. 11,485,616 Shares
FaceValue 10
About Parnax Lab Ltd.
Parnax Lab, earlier known as Krishnadeep Trade and Investments, incorporated in the year 1982, engages in investing and financial businesses in India. The company is based in Mumbai, India. In 2012 the company has changed its name from Krishna Deep Trade & Investments Ltd. to Parnax Lab Ltd. "

Parnax Lab Ltd. Delivery

Delivered Qty
Traded Qty

Parnax Lab Ltd. Performance

1 Day
-0.48%
1 Week
+0.73%
1 Month
-5.04%
3 Month
+0.05%
6 Month
-6.10%
1 Year
+32.94%
2 Year
-13.75%
5 Year
+167.10%
10 Year
+117.35%

Parnax Lab Ltd. Fundamental Ratios

9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 18.5 9.5 12.51 3.31 9.69 -8.51 -1.11 20.93 15.91
Return on Capital Employed (%) 16.35 11.47 13.73 10.49 11.59 3.27 5.83 17.34 15.2
Return on Assets (%) 5.12 3.09 4.48 1.22 3.63 -2.89 -0.34 6.36 5.78

Parnax Lab Ltd. Balance Sheet

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 25 28 31 33 36 33 33 48 62 67
Non Curr. Liab. 27 23 18 18 23 22 19 24 20 24
Curr. Liab. 31 29 36 37 36 52 54 81 63 66
Minority Int. 0 0 0 0 0 0 0 0 0 0
Equity & Liab. 83 79 86 87 95 107 106 153 145 158
Non Curr. Assets 45 49 55 51 58 62 67 79 84 92
Curr. Assets 38 31 31 36 37 42 36 71 57 66
Misc. Exp. not W/O 0
Total Assets 83 79 86 87 95 107 106 153 145 158

Parnax Lab Ltd. Profit and Loss

Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 103 71 95 106 109 95 90 163 168 183
Other Income 1 1 1 1 2 1 0 0 1 1
Total Income 104 72 96 107 111 96 90 163 168 184
Total Expenditure -91 -61 -82 -96 -99 -89 -80 -140 -145 -161
PBIDT 13 11 13 11 12 7 10 23 24 23
Interest -4 -4 -5 -4 -4 -5 -5 -5 -5 -5
Depreciation -3 -3 -4 -4 -4 -4 -5 -6 -7 -7
Taxation -1 -1 -1 -2 -1 -1 0 -4 -4 -3
Exceptional Items
PAT 4 3 4 1 3 -3 0 8 9 9
Minority Interest 0 0 0 0 0 0 0
Share Associate
Other Related Items
Consolidated Net Profit 4 3 4 1 3 -3 0 8 9 9
Adjusted EPS 5 3 4 1 4 -3 0 8 8 8

Parnax Lab Ltd. Cash Flow

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 0 0 3 16 13 9 9 6 9 21
Cash Fr. Inv. -6 -4 -6 -10 -5 -11 -13 -7 -17 -10
Cash Fr. Finan. 6 6 1 -5 -7 1 5 0 12 -14
Net Change 0 1 -2 0 1 -1 0 0 4 -3
Cash & Cash Eqvt 1 2 0 0 1 0 0 0 4 1

Parnax Lab Ltd. Shareholding Pattern

9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 62.59 67.58 67.58 72.30 72.30 72.30 72.30 72.30 72.30
Public 37.41 32.42 32.42 27.70 27.70 27.70 27.70 27.70 27.70
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 14.68 11.78 11.78 9.41 9.41 9.41 9.41 9.41 9.41

Parnax Lab Ltd. Announcements

Tue, 13 Feb 2024
Results-Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2023
Kindly find attached herewith the Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31 2023 along with Limited Review Report.
Tue, 13 Feb 2024
Board Meeting Outcome for Results-Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2023
Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday 13th February 2024 at its Registered Office the Board inter alia has transacted the following business:1. Considered and Approved the Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and nine months ended 31st December 2023 along with Limited Review Report thereon.A Copy of Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and nine months ended 31st December 2023 along with Limited Review Report thereon pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations 2015 is enclosed herewith.The meeting of the Board of Directors Commenced at 4.00 P.M. and Concluded at 04.30 P.M.
Sat, 03 Feb 2024
Board Meeting Intimation for Approval Of Unaudited Stand-Alone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31 2023.
PARNAX LAB LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve Standalone and Consolidated Un-audited IND- AS Compliant Financial Results along with Limited Review Report for the quarter (Q3) and Nine Months ended 31st December 2023 pursuant to Regulation 33 of Listing Obligation and Disclosure Requirement 2015 and any other business with the permission of the Chair. Kindly acknowledge the receipt of the same and Oblige

Parnax Lab Ltd. Technical Scans

Fri, 23 Feb 2024
High Decrease in 1 Month High Decrease in 1 Month
High Increase in 1 Year High Increase in 1 Year
High Increase in 5 Years High Increase in 5 Years
Thu, 22 Feb 2024
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High

Parnax Lab Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 374,572.18 1,560.95 +0.2%
Cipla Ltd. 118,375.92 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. 107,511.08 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. 97,345.81 6,742.15 -0.4%
Divi's Laboratories Ltd. 96,748.70 3,636.05 -0.3%
Zydus Lifesciences Ltd. 93,335.34 922.10 +1.9%
Torrent Pharmaceuticals Ltd. 88,913.00 2,627.10 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 42.06 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-12 31.92 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.56 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 123.33 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-12 69.96 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.39 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 59.51 2,627.10 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 6.00 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-12 4.57 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 4.00 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 14.41 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-12 7.42 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-12 4.80 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.43 2,627.10 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 0.02 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,627.10 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,627.10 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 12.85 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,627.10 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,627.10 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,560.95 +0.2%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,466.20 +0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,445.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,742.15 -0.4%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,636.05 -0.3%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 922.10 +1.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,627.10 +0.7%

Parnax Lab Ltd. FAQ's

What is Parnax Lab share price?

Can I buy Parnax Lab shares now?

What is the Market Cap of Parnax Lab?

What are the key metrics to analyse Parnax Lab?

What is the 52 Week High and Low of Parnax Lab?

What is the trend of Parnax Lab share price?